12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vascepa icosapent ethyl regulatory update

Amarin disclosed in a Nov. 21 SEC filing that FDA did not accept for review the company's appeal of the agency's rescission of an SPA for the Phase III ANCHOR trial. The trial evaluated Vascepa icosapent ethyl in combination with statins to treat high triglycerides - defined as triglyceride levels >=200 mg/dL and <500...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >